TN-10试验进展风险可推广至欧洲人群:有无1型糖尿病一级亲属均适用
本研究基于TN-10安慰剂组(n=32)与德国Fr1da筛查项目(n=152)的2期1型糖尿病参与者,回顾性比较进展至3期的时间。结果显示两组进展风险相当(HR=1.3,95%CI 0.8-2.1),校正显著预后因素后HR=1.1(95%CI 0.6-2.1);Fr1da组中有无一级亲属者进展时间相似。结论提示TN-10的进展风险可能可推广至欧洲有无一级亲属人群。
要点
- TN-10安慰剂组与Fr1da组进展至3期1型糖尿病风险相当(HR=1.3,95%CI 0.8-2.1)。
- 校正抗IA-2抗体、HbA1c>5.7%和120分钟OGTT后,校正HR=1.1(95%CI 0.6-2.1)。
- Fr1da组中有无一级亲属者进展时间相似,年龄亚组分析影响极小。
核心结论
- TN-10安慰剂组与Fr1da组进展至3期1型糖尿病的时间相似。
- 有无1型糖尿病一级亲属的参与者进展时间相似。
- TN-10试验的进展风险可能可推广至欧洲有无一级亲属人群。
研究设计与样本
- 回顾性研究,使用TN-10安慰剂组(n=32)和德国Fr1da人群筛查项目(n=152)的2期1型糖尿病参与者数据。
- 研究仅具有检测大差异的足够把握度。
主要发现
- TN-10安慰剂组与Fr1da组进展至3期1型糖尿病的风险相当(HR=1.3,95%CI 0.8-2.1)。
- 校正抗IA-2抗体、HbA1c>5.7%和120分钟口服葡萄糖耐量试验后,校正HR=1.1(95%CI 0.6-2.1)。
- Fr1da组中有一级亲属(n=45)与无一级亲属(n=107)者进展至3期的时间相似。
- 年龄亚组分析显示年龄对进展时间影响极小。
关键数值与推荐
- 进展风险比较:TN-10安慰剂组 vs Fr1da组,HR=1.3(95%CI 0.8-2.1)。
- 校正后HR=1.1(95%CI 0.6-2.1),校正因素包括抗IA-2抗体、HbA1c>5.7%和120分钟OGTT。
- Fr1da组有FDR n=45,无FDR n=107,进展时间相似。
临床怎么用
- TN-10试验的进展风险数据或可参考用于欧洲有无1型糖尿病一级亲属的2期患者。
- 临床评估进展风险时需考虑抗IA-2抗体、HbA1c>5.7%和120分钟OGTT等预后因素。
局限性
- 研究仅具有检测大差异的足够把握度。
- 为回顾性研究,样本量有限(TN-10安慰剂组n=32)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In the TrialNet 10 Anti-CD3 Prevention (TN-10) trial, teplizumab delayed onset of stage 3 type 1 diabetes in U.S. and Canadian individuals with stage 2 disease who had a relative with type 1 diabetes. Here, the generalizability of the population risk in TN-10 to a European population with or without first-degree relatives (FDRs) with type 1 diabetes was investigated. RESEARCH DESIGN AND METHODS: This retrospective study used data from participants with stage 2 type 1 diabetes from the TN-10 placebo arm and the Fr1da population-based screening program in Germany (Fr1da group) to investigate time to progression from stages 2-3 type 1 diabetes. The study only had sufficient power to detect large differences. RESULTS: Risk of progression to stage 3 type 1 diabetes was comparable between the TN-10 placebo arm (n = 32) and the Fr1da group (n = 152; hazard ratio [HR] = 1.3 [95% CI 0.8-2.1]). Once prognostic factors significantly associated with progression in this study (anti-IA-2 antibodies, HbA1c >5.7%, and 120-min oral glucose tolerance test) were included in the model, the adjusted HR was 1.1 (95% CI 0.6-2.1). Fr1da group participants with (n = 45) and without (n = 107) FDRs with type 1 diabetes had similar time to progression to stage 3. Age-based subanalysis demonstrated minimal impact of age on progression time. CONCLUSIONS: Time to progression to stage 3 appeared similar between the TN-10 placebo arm and the Fr1da group and between participants with and without FDRs with disease. Results suggest progression risk from the TN-10 trial may be generalizable to European populations with or without FDRs with type 1 diabetes.
引用
- Koeger M, Winkler C, Hummel S, et al. Generalizability of Progression Risk in the TN-10 Trial to a European Population With or Without a First-Degree Relative With Type 1 Diabetes. Diabetes Care. 2026. PMID: 41118628. doi:10.2337/dc25-1021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。